

FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P28604Application No.  
10/551,780INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)Applicant  
Motoharu SEIKI et al.Filing Date  
October 3, 2005Group  
1642

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS

		DOCUMENT (Including Author, Title, Date, Pertinent Pages, Etc.)
/MH/		Hatakeyama H et al.; "Tumor targeting of doxorubicin by anti-MT 1-MIVIP antibody-modified PEG liposomes." Int. J. Pharm. 342(1-2): 194-200 (2007). Epub 2007 May 10.
/MH/		Atobe K et al.; "In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP)." Biol. Pharm. Bull. 30(5): 972-8 (2007).
/MH/		Abstracts of the 20th annual meeting of the Academy of Pharmaceutical Science and Technology, Japan (2005), Kobayashi H et al., "Study on formulation of anti-MT1-MMP antibody-bound liposome-Optimization of binding amount of antibody-" accompanied by an English Translation.

EXAMINER

/Mark Halvorson/

DATE CONSIDERED

06/28/2011

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.